Search
Organon & Co
OGNAdd to Watchlist
13.475USD
+0.025+0.19%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
3.50BMarket Cap
14.27P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.19%
5 Days
+0.41%
1 Month
+0.34%
6 Months
+90.06%
Year to Date
+87.94%
1 Year
+37.50%
Key Figures
13.450Open
13.475High
3.10MVolume
14.27P/E TTM
3.60P/E Dynamic
0.080Dividend TTM
1.19%Turnover Ratio
13.450Prev. Close
13.441Low
22.18MTurnover
4.05P/E Static
3.87P/B
0.59%Div Yield TTM
1.88%ROA
13.48052wk High
1.10Volume Ratio
864.00MNet Profit
259.98MShares
0.9440EPS TTM
1.53Beta
34.05%ROE
5.69052wk Low
0.26%Amplitude
53.63%Gross Margin
3.50BMarket Cap
0.10Reward/Risk
3.09%Risk Rate
TradingKey Stock Score of Organon & Co
Currency: USD Updated: 2026-06-23Key Insights
Organon & Co's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 80 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 10.80.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Organon & Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Organon & Co Highlights
StrengthsRisks
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 34.38%.
Overvalued
The company’s latest PE is 14.25, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 239.27M shares, decreasing 1.64% quarter-over-quarter.
Held by Irving Kahn
Star Investor Irving Kahn holds 2.48M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.41.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
10.800
Target Price
-19.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Organon & Co News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Organon & Co Info
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Ticker SymbolOGN
CompanyOrganon & Co
CEOMorrissey (Joseph T)
Websitehttps://www.organon.com/
Related Instruments
+0.90%
+0.82%
+0.83%
+0.08%
+0.88%
-0.14%
+1.27%
-0.02%
+0.09%
-2.71%
+1.45%
-0.89%
-1.86%
-0.65%
+0.41%
0.00%
+0.87%
+1.80%
-0.11%
-0.76%Popular Instruments
69.744
-0.015 (-0.02%)
293.080
-1.220 (-0.41%)
199.000
-1.040 (-0.52%)
4005.650
+6.910 (+0.17%)
643.830
-26.920 (-4.01%)
1914.460
-49.140 (-2.50%)
1048.510
-3.260 (-0.31%)
345.290
-0.840 (-0.24%)
60890.010
-35.990 (-0.06%)
375.530
-6.080 (-1.59%)
FAQs
What is the current price of Organon & Co (OGN)?
The current price of Organon & Co (OGN) is 13.46.
What is the symbol of Organon & Co?
The ticker symbol of Organon & Co is OGN.
What is the 52-week high of Organon & Co?
The 52-week high of Organon & Co is 13.48.
What is the 52-week low of Organon & Co?
The 52-week low of Organon & Co is 5.69.
What is the market capitalization of Organon & Co?
The market capitalization of Organon & Co is 3.53B.
Is Organon & Co (OGN) currently rated as Buy, Hold, or Sell?
According to analysts, Organon & Co (OGN) has an overall rating of signal_hold, with a price target of 10.80.
What is the Earnings Per Share (EPS TTM) of Organon & Co (OGN)?
The Earnings Per Share (EPS TTM) of Organon & Co (OGN) is 0.72.
